Table S2.
Concomitant use of short-acting beta 2-agonists in the ITT population
| Randomized group | Short-acting beta 2-agonists use
|
|
|---|---|---|
| Baseline period, n (%) | Double-blind period, n (%) | |
| 160 μg/day (N=119) | 110 (92.4) | 108 (90.8) |
| 320 μg/day (N=122) | 105 (86.1) | 103 (84.4) |
| 640 μg/day (N=126) | 108 (85.7) | 108 (85.7) |
Abbreviation: ITT, intention-to-treat.